Iodomethane

Iodomethane

SCHEMBL871394

CC(=O)C(CC(C)C)CN(C)C.CI

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KISS1R Q969F8 4/20 0.43
SLC1A3 P43003 1/20 0.35
SLC1A2 P43004 1/20 0.35
CPA1 P15085 1/20 0.33
NPC1 O15118 1/20 0.33
MAPT P10636 1/20 0.33
MAPK1 P28482 1/20 0.33
HTT P42858 1/20 0.33
RAB9A P51151 1/20 0.33
ATM Q13315 1/20 0.33
MME P08473 2/20 0.32
ALDH1A1 P00352 2/20 0.31
RNPEP Q9H4A4 1/20 0.31
SLC7A5 Q01650 1/20 0.31
MMP1 P03956 1/20 0.31
MMP2 P08253 1/20 0.31
MMP8 P22894 1/20 0.31
MMP13 P45452 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL234393 0.96 KISS1R (0.46) KISS1RSLC1A3SLC1A2CPA1NPC1
Oxalic Acid SCHEMBL19024409 0.90 KISS1R (0.42) KISS1RSLC1A3SLC1A2CPA1NPC1
Heptane SCHEMBL19024431 0.85 KISS1R (0.42) KISS1RMAPK1MMP8
Iodomethane SCHEMBL16760124 0.78 TSHR (0.43) SLC1A3SLC1A2NPC1MAPTMAPK1
Citric Acid SCHEMBL19024416 0.78 ALDH1A1 (0.46) KISS1RSLC1A3SLC1A2MAPTMAPK1
SCHEMBL5672721 0.77 KISS1R (0.61) KISS1RSLC1A3SLC1A2CPA1MME
SCHEMBL27527680 0.74 KISS1R (0.59) KISS1RSLC1A3SLC1A2CPA1MME
Ammonia Solution, Strong SCHEMBL27748255 0.74 KISS1R (0.59) KISS1RSLC1A3SLC1A2CPA1MME
SCHEMBL16512045 0.74 ANPEP (0.30)
SCHEMBL18934271 0.73 TSHR (0.46) SLC1A3SLC1A2NPC1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012081031-A1 PROCESS FOR PREPARING TETRABENAZINE ENALTEC LABS PVT. LTD. (IN) 2012-06-21 WO claimed
US-8357697-B2 Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto NEUROCRINE BIOSCIENCES, INC. (US) 2013-01-22 US disclosed
EP-2081929-B1 SUBSTITUTED 3-ISOBUTYL-9, 10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-A]ISOQUINOLIN-2-OL COMPOUNDS AND METHODS RELATING THERETO NEUROCRINE BIOSCIENCES INC (US) 2013-01-09 EP disclosed
WO-2012081031-A1 PROCESS FOR PREPARING TETRABENAZINE ENALTEC LABS PVT. LTD. (IN) 2012-06-21 WO disclosed
US-20120077839-A1 SUBSTITUTED 3-ISOBUTYL-9,10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-A]ISOQUINOLIN-2-OL COMPOUNDS AND METHODS RELATING THERETO NEUROCRINE BIOSCIENCES, INC. (US) 2012-03-29 US disclosed
US-8039627-B2 Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto NEUROCRINE BIOSCIENCES, INC. (US) 2011-10-18 US disclosed
EP-2081929-A1 SUBSTITUTED 3-ISOBUTYL-9, 10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDOÝ2,1-A¨ISOQUINOLIN-2-OL COMPOUNDS AND METHODS RELATING THERETO NEUROCRINE BIOSCIENCES, INC. (US) 2009-07-29 EP disclosed
US-20080167337-A1 SUBSTITUTED 3-ISOBUTYL-9,10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-A]ISOQUINOLIN-2-OL COMPOUNDS AND METHODS RELATING THERETO NEUROCRINE BIOSCIENCES, INC. 2008-07-10 US disclosed
WO-2008058261-A1 SUBSTITUTED 3-ISOBUTYL-9, 10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-A] ISOQUINOLIN-2-OL COMPOUNDS AND METHODS RELATING THERETO NEUROCRINE BIOSCIENCES, INC. (US) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167337-A1 SUBSTITUTED 3-ISOBUTYL-9,10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-A]ISOQUINOLIN-2-OL COMPOUNDS AND METHODS RELATING THERETO SLC18A2, SLC6A2, SLC18A3 KISS1R 2503/4885SLC1A3 74/4885SLC1A2 28/4885
US-20120077839-A1 SUBSTITUTED 3-ISOBUTYL-9,10-DIMETHOXY-1,3,4,6,7,11B-HEXAHYDRO-2H-PYRIDO[2,1-A]ISOQUINOLIN-2-OL COMPOUNDS AND METHODS RELATING THERETO SLC18A2, SLC6A2, SLC18A3 KISS1R 2503/4885SLC1A3 74/4885SLC1A2 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.